Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
124I-EV PET Imaging in Solid Tumors
NCT05322512Not yet recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- May 2024
- Primary completion
- Dec 2024
01
Overview
Open-label trial of iodine-124-labeled enfortumab vedotin in solid tumor, sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Standardized Uptake Value at 2 years. Planned start May 2024; status: not yet recruiting.
02
Drugs
iodine-124-labeled enfortumab vedotin
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05322512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05322512.